reserpine | 873409-80-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 育亨宾生物碱
• 英文名称: reserpine
• 英文别名: Reserpin；methyl 2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2’,3’: 3,4]pyrido[1,2-b]isoquinoline-1-carboxylate；Isoreserpin；methyl 6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
• CAS: 873409-80-4
• 化学式: C₃₃H₄₀N₂O₉
• 分子量: 608.689
• InChiKey: QEVHRUUCFGRFIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  10

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：由于缺乏关于在哺乳期间使用利血平的信息，并且它可能会对哺乳婴儿产生不利影响，因此可能更倾向于选择另一种药物，特别是在哺乳新生儿或早产儿时。 ◉ 对哺乳婴儿的影响：尽管没有充分的文献记录，但据说利血平会导致哺乳婴儿鼻塞和增加气管支气管分泌物。[1] ◉ 对泌乳和母乳的影响：据报道，利血平曾引起乳汁过多，并且曾被用来增加乳汁产量，尽管这种用途已经过时。[2][3][4]

◉ Summary of Use during Lactation:Because no information is available on the use of reserpine during breastfeeding and it might adversely affect the breastfed infant, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. ◉ Effects in Breastfed Infants:Although not well documented, reserpine is said to cause nasal stuffiness and increased tracheobronchial secretions in breastfed infants.[1] ◉ Effects on Lactation and Breastmilk:Reserpine has reportedly caused galactorrhea and has been used to increase breastmilk production, although it is obsolete for this use.[2][3][4]

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  3-溴丙炔 、 reserpine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  CN116023376

  摘要：

  公开号：

文献信息

• Croos-B Structure Binding Compounds
  申请人：Gebbink Martijn Frans Ben Gerard

  公开号：US20080267948A1

  公开（公告）日：2008-10-30

  The invention relates to the field of biochemistry, biophysical chemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structure conformation. Even more particular, the invention relates to compounds capable of binding to a compound with cross-β structure conformation, i.e. cross-β structure binding compounds and uses thereof.

  本发明涉及生物化学、生物物理化学、分子生物学、结构生物学和医学领域。更具体地说，本发明涉及交叉β结构构象。更具体地说，本发明涉及能够结合具有交叉β结构构象的化合物的化合物，即交叉β结构结合化合物及其用途。
• A material and composition for reducing blood pressure
  申请人：MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：EP0005057A1

  公开（公告）日：1979-10-31

  A material and composition for reducing blood pressure are provided. The blood pressure in animals is reduced by administering tyrosine, a tyrosine precursor, tryptophan or mixtures thereof, either alone or in combination with a substance which is known to reduce blood pressure. A composition is provided comprising a unit dosage form of tyrosine, a precursor for tyrosine, tryptophan or mixtures thereof and a substance which is known to reduce blood pressure.

  本发明提供了一种用于降低血压的材料和组合物。 通过单独或与已知可降低血压的物质结合施用酪氨酸、酪氨酸前体、色氨酸或其混合物，可降低动物的血压。 本发明提供了一种组合物，该组合物由单位剂量的酪氨酸、酪氨酸前体、色氨酸或其混合物和已知可降低血压的物质组成。
• Method of increasing milk production
  申请人：——

  公开号：US20030139420A1

  公开（公告）日：2003-07-24

  The invention relates generally to the use of pharmaceutical compositions to increase milk production alone or in combination with certain biological active ingredients. Specifically, the method relates to the use of pharmaceutical compositions that will act on the feedback of the intrinsic regulatory pathway in the mammalian mammary gland. The present invention provides for as a method of increasing bovine milk production as well as a method of correcting certain human lactation abnormalities. Preferably, the compounds used in the methods of the present invention are one or more active agents capable of inhibiting peripheral aromatic amino acid decarboxylase (AADC) enzymes, peripheral tryptophan hydroxylase (TPH) enzymes, peripheral serotonin (5-HT) enzymes, or a combination of enzymes thereof.

  本发明一般涉及使用药物组合物，单独或与某些生物活性成分结合使用以增加产奶量。具体地说，该方法涉及药物组合物的使用，这些药物组合物将作用于哺乳动物乳腺内在调节途径的反馈。本发明提供了一种增加牛产奶量的方法以及一种纠正人类某些泌乳异常的方法。优选地，本发明方法中使用的化合物是一种或多种能够抑制外周芳香族氨基酸脱羧酶（AADC）、外周色氨酸羟化酶（TPH）、外周血清素（5-HT）酶或其组合酶的活性剂。
• TREATMENT OF HUMAN LACTATION FAILURE
  申请人：Pharmacia & Upjohn Aktiebolag

  公开号：EP0652767B1

  公开（公告）日：1999-09-15
• COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF
  申请人：University of Saskatchewan

  公开号：US20140312218A1

  公开（公告）日：2014-10-23

  The present disclosure relates to functionalized nanodiamonds comprising at least one MALDI matrix covalently bonded to a nanodiamond and compositions comprising the same. The present disclosure also relates to methods of performing matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS), for example on small molecules, using matrices comprising at least one MALDI matrix covalently bonded to a nanodiamond.

表征谱图